Abstract:
The present invention provides antibodies or antigen binding fragments thereof including single chain variable fragment (scFv) antibodies that specifically bind to the blood brain barrier in vivo and methods of use.
Abstract:
The present invention provides antibodies or antigen-binding fragments thereof including single chain variable fragment (scFv) antibodies that specifically bind to and translocate the blood-brain barrier and methods of use.
Abstract:
This invention provides antibodies that bind brain endothelial cell receptors resulting in endocytosis/transcytosis of the receptor and bound ligands. In some embodiments, the ligand comprises the antibody in combination with a pharmaceutically active compound and the antibody directs delivery of the compound across the blood brain barrier (BBB). The invention also provides methods of identifying endothelial cell specific antibodies by panning the library against cultured cell monolayers. The invention further allows for identifying endothelial cell receptors that bind the antibody thereby providing target receptors against which to isolate further cognate ligands and their associated transport systems and by which to identify transcytosis transporters targeted by the antibodies.
Abstract:
The present disclosure provides isolated polypeptides comprising variable lymphocyte receptors that specifically bind the blood brain barrier, compositions, and methods of use.
Abstract:
The present invention provides antibodies or antigen binding fragments thereof including single chain variable fragment (scFv) antibodies that specifically bind to the blood brain barrier in vivo and methods of use.
Abstract:
In one embodiment, the present invention is a method of creating a fully-human blood-brain barrier (BBB) model, comprising the steps of (a) obtaining a mixture of neural cells and brain microvascular endothelial cells (BMECs), wherein the neural cells and BMECs that comprise the mixture were produced from the differentiation of human pluripotent stem cells (hPSCs); (b) purifying BMECs from the mixture of neural cells and BMECs of step (a); and (c) co-cuituring the purified BMECs with a ceil type selected from the group consisting of pericytes, astrocytes and differentiated neural progenitor ceils (NPCs), wherein a blood brain barrier model is created. In another embodiment the present invention is a method of creating a retinoic acid (RA)-enhanced or RA-like compound-enhanced mammalian blood-brain barrier (BBB) model, comprising the steps of: (a) obtaining a mixture of neural cells and brain microvascular endothelial ceils (BMECs) in the presence of RA or RA-like compound, wherein the mixture of neural ceils and BMECs was produced from the differentiation of human pluripotent stem ceils (hPSCs); (b) purifying BMECs from the mixture of neural cells and BMECs; and co- cuituring the purified BMECs with a cell type selected from the group consisting of astrocytes, pericytes and differentiated neural progenitor ceils (NPCs), wherein a BBB model is created.